Search

Your search keyword '"Stradella, Agostina"' showing total 173 results
Start Over Author "Stradella, Agostina"
173 results on '"Stradella, Agostina"'

1. Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival—a propensity score cohort study

Author

Fernandez-Gonzalez, Sergi, Falo, Catalina, Pla, Maria J., Campos, Miriam, Ortega-Exposito, Carlos, Ortega, Raul, Vicente, Maria, Petit, Ana, Bosch-Schips, Jan, Bajen, Maria Teresa, Reyes, Gabriel, Martínez, Evelyn, González-Viguera, Javier, Peñafiel, Judith, Stradella, Agostina, Pernas, Sonia, Ponce, Jordi, and Garcia-Tejedor, Amparo

Published
2024
Full Text
View/download PDF

2. Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial

Author

Llombart-Cussac, Antonio, Prat, Aleix, Pérez-García, José Manuel, Mateos, José, Pascual, Tomás, Escrivà-de-Romani, Santiago, Stradella, Agostina, Ruiz-Borrego, Manuel, de las Heras, Begoña Bermejo, Keyaerts, Marleen, Galvan, Patricia, Brasó-Maristany, Fara, García-Mosquera, Juan José, Guiot, Thomas, Gion, María, Sampayo-Cordero, Miguel, Di Cosimo, Serena, Pérez-Escuredo, Jhudit, de Frutos, Manuel Atienza, Cortés, Javier, and Gebhart, Geraldine

Published
2024
Full Text
View/download PDF

4. Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)

Author

Turner, Nicholas, Saura, Cristina, Aftimos, Philippe, van den Tweel, Evelyn, Oesterholt, Mayke, Koper, Norbert, Colleoni, Marco, Kaczmarek, Emilie, Punie, Kevin, Song, Xinni, Armstrong, Anne, Bianchi, Giulia, Stradella, Agostina, Ladoire, Sylvain, Lim, Joline Si Jing, Quenel-Tueux, Nathalie, Tan, Tira J., Escrivá-de-Romaní, Santiago, OʼShaughnessy, Joyce, Kuip, Evelien, de Vries, Elisabeth G.E., Menke-van der Houven van Oordt, Willemien, Aftimos, Philippe, Papadimitriou, Konstantinos, Denys, Hannelore, Punie, Kevin, Jerusalem, Guy, Borms, Marleen, Duhoux, François, Turner, Nicholas, Macpherson, Iain, Armstrong, Anne, Levitt, Nicola, Palmieri, Carlo, Borley, Annabel, Crook, Timothy, Vega Alonso, Estela, Morales, Serafin, de Romani Muñoz, Santiago Escriva, Stradella, Agostina, Jerez Gilarranz, Yolanda, Anton, Antonio, Ponce, Jose Juan, Adamo, Barbara, Cortes Castan, Javier, Martinez, Maria, Petit, Thierry, Kaczmarek, Emilie, Ladoire, Sylvain, Quenel Tueux, Nathalie, Teixeira, Luis, Christophe Thery, Jean, Abadie-Lacourtoisie, Sophie, Lortholary, Alain, Luporsi, Elisabeth, Orfeuvre, Hubert, Bonnin, Nathalie, Bianchini, Giampaolo, Piacentini, Federico, Cognetti, Francesco, Marchetti, Paolo, Maiello, Evaristo, Cazzaniga, Marina, Guarneri, Valentina, Colleoni, Marco, Doni, Laura, Bordonaro, Roberto, Zamagni, Claudio, Bianchi, Giulia, Biganzoli, Laura, Thirlwell, Michael, Song, Xinni, Joy, Anil, Taylor, Sara, Helsten, Teresa, Chaudhry, Madhu, Ali, Haythem, Dakhil, Shaker, Mowat, Rex, Brufsky, Adam, Cobleigh, Melody, Modiano, Manuel, Cairo, Michelina, Meshad, Michael, Danso, Michael A., Andersen, Jay, Harroff, Allyson, Owera, Rami, Favret, Anne, OʼShaughnessy, Joyce, Pluard, Timothy, Rosenblatt, Paula, Jain, Sharad, Jensen, Jeanette Dupont, Jeppesen, Nina, Wedervang, Kim, Edlund, Per, Lindman, Henrik, Altena, Renske, Klint, Leif, Jing Ying, Tira Tan, and Si Jing, Joline Lim

Published
2024
Full Text
View/download PDF

5. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab

Author

Gion, María, García-Mosquera, Juan José, Pérez-García, José Manuel, Peg, Vicente, Ruiz-Borrego, Manuel, Stradella, Agostina, Bermejo, Begoña, Guerrero, José Antonio, López-Montero, Laura, Mancino, Mario, Rodríguez-Morató, José, Antonarelli, Gabriele, Sampayo-Cordero, Miguel, Llombart-Cussac, Antonio, and Cortés, Javier

Published
2024
Full Text
View/download PDF

7. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

Author

Pérez-García, José Manuel, Cortés, Javier, Ruiz-Borrego, Manuel, Colleoni, Marco, Stradella, Agostina, Bermejo, Begoña, Dalenc, Florence, Escrivá-de-Romaní, Santiago, Calvo Martínez, Lourdes, Ribelles, Nuria, Marmé, Frederik, Cortés, Alfonso, Albacar, Cinta, Gebhart, Geraldine, Prat, Aleix, Kerrou, Khaldoun, Schmid, Peter, Braga, Sofia, Di Cosimo, Serena, Gion, Maria, Antonarelli, Gabriele, Popa, Crina, Szostak, Emilia, Alcalá-López, Daniel, Gener, Petra, Rodríguez-Morató, Jose, Mina, Leonardo, Sampayo-Cordero, Miguel, and Llombart-Cussac, Antonio

Published
2024
Full Text
View/download PDF

8. Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact

Author

Garcia-Tejedor, Amparo, Falo, Catalina, Fernandez-Gonzalez, Sergi, Laplana, Maria, Gil-Gil, Miguel, Soler-Monso, Teresa, Martinez-Perez, Evelyn, Calvo, Iris, Calpelo, Hugo, Bajen, Maria-Teresa, Benitez, Ana, Ortega, Raul, Petit, Anna, Guma, Anna, Campos, Miriam, Stradella, Agostina, Lopez-Ojeda, Ana, Ponce, Jordi, Pla, Maria J., and Pernas, Sonia

Published
2023
Full Text
View/download PDF

11. Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.

Author

Pérez García, José Manuel, primary, Cortes, Javier, additional, Ruiz-Borrego, Manuel, additional, Stradella, Agostina, additional, Bermejo, Begoña, additional, Escrivá-de-Romaní, Santiago, additional, Calvo, Lourdes, additional, Gebhart, Geraldine, additional, Kerrou, Khaldoun, additional, García-Mosquera, Juan José, additional, Gion, Maria, additional, Antonarelli, Gabriele, additional, López-Montero, Laura, additional, Rodríguez-Morató, José, additional, Mina, Leonardo, additional, Sampayo-Cordero, Miguel, additional, and Llombart-Cussac, Antonio, additional

Published
2024
Full Text
View/download PDF

12. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

Author

Pérez-García, José Manuel, Gebhart, Geraldine, Ruiz Borrego, Manuel, Stradella, Agostina, Bermejo, Begoña, Schmid, Peter, Marmé, Frederik, Escrivá-de-Romani, Santiago, Calvo, Lourdes, Ribelles, Nuria, Martinez, Noelia, Albacar, Cinta, Prat, Aleix, Dalenc, Florence, Kerrou, Khaldoun, Colleoni, Marco, Afonso, Noemia, Di Cosimo, Serena, Sampayo-Cordero, Miguel, Malfettone, Andrea, Cortés, Javier, and Llombart-Cussac, Antonio

Published
2021
Full Text
View/download PDF

13. The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials

Author

Ortega Expósito, Carlos, Falo, Catalina, Pernas, Sonia, Pérez Carton, Samuel, Gil Gil, Miguel, Ortega, Raul, Pérez Montero, Héctor, Stradella, Agostina, Martinez, Evelyn, Laplana, Maria, Salinas, Sira, Luzardo, Ana, Soler, Teresa, Fernández Montoli, Maria Eulalia, Azcarate, Juan, Guma, Anna, Petit, Anna, Benitez, Ana, Bajen, Maite, Reyes Junca, Jose G., Campos, Miriam, Ruiz, Raquel, Ponce, Jordi, Pla, Maria J., and García Tejedor, Amparo

Published
2021
Full Text
View/download PDF

14. Plasma neurofilament light chain levels in chemotherapy‐induced peripheral neurotoxicity according to type of anticancer drug.

Author

Velasco, Roser, Marco, Carla, Domingo‐Domenech, Eva, Stradella, Agostina, Santos, Cristina, Laquente, Berta, Ferrer, German, Argyriou, Andreas A., and Bruna, Jordi

Abstract

Background and purpose: A real‐time biomarker in chemotherapy‐induced peripheral neurotoxicity (CIPN) would be useful for clinical decision‐making during treatment. Neurofilament light chain (NfL) can be detected in blood in the case of neuroaxonal damage. The aim of the study was to compare the levels of plasma NfL (pNfL) according to the type of chemotherapeutic agent and the severity of CIPN. Methods: This single‐center prospective observational longitudinal study included patients treated with paclitaxel (TX; n = 34), brentuximab vedotin (BV; n = 29), or oxaliplatin (PT; n = 19). All patients were assessed using the Total Neuropathy Score–clinical version and Common Terminology Criteria for Adverse Events before, during, and up to 6–12 months after the end of treatment. Nerve conduction studies (NCS) were performed before and after chemotherapy discontinuation. Consecutive plasma samples were analyzed for NfL levels using a Simoa® analyzer. Changes in pNfL were compared between groups and were eventually correlated with clinical and NCS data. Clinically relevant (CR) CIPN was considered to be grade ≥ 2. Results: Eighty‐two patients, mostly women (59.8%), were included. One third of the patients who received TX (29.4%), BV (31%), or PT (36.8%) developed CR‐CIPN, respectively, without differences among them (p = 0.854). Although pNfL significantly increased during treatment and decreased throughout the recovery period in all three groups, patients receiving TX showed significantly greater and earlier changes in pNfL levels compared to the other agents (p < 0.001). Conclusions: A variable change in pNfL is observed depending on the type of agent and mechanism of neurotoxicity with comparable CIPN severity, strongly implying the need to identify different cutoff values for each agent. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.

Author

Gebhart, Geraldine, Keyaerts, Marleen, Guiot, Thomas, Flamen, Patrick, Ruiz-Borrego, Manuel, Stradella, Agostina, Bermejo, Begoña, Escriva-de-Romani, Santiago, Calvo Martínez, Lourdes, Ribelles, Nuria, Fernandez-Abad, María, Albacar, Cinta, Colleoni, Marco, Garrigos, Laia, Atienza de Frutos, Manuel, Dalenc, Florence, Prat, Aleix, Marmé, Frederik, Schmid, Peter, and Kerrou, Khaldoun

Published
2024
Full Text
View/download PDF

16. Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.

Author

Llombart-Cussac, Antonio, Prat, Aleix, Pérez-García, José Manuel, Mateos, José, Pascual, Tomás, Escrivà-de-Romani, Santiago, Stradella, Agostina, Ruiz-Borrego, Manuel, de las Heras, Begoña Bermejo, Keyaerts, Marleen, Galvan, Patricia, Brasó-Maristany, Fara, García-Mosquera, Juan José, Guiot, Thomas, Gion, María, Sampayo-Cordero, Miguel, Di Cosimo, Serena, Pérez-Escuredo, Jhudit, de Frutos, Manuel Atienza, and Cortés, Javier

Subjects
BREAST, HER2 positive breast cancer, EARLY diagnosis, MAGNETIC resonance imaging, HER2 protein, NEOADJUVANT chemotherapy
Abstract

Background: The PHERGain study (NCT03161353) is assessing early metabolic responses to neoadjuvant treatment with trastuzumab-pertuzumab and chemotherapy de-escalation using a [18Fluorine]fluorodeoxyglucose-positron emission tomography ([18F]FDG-PET) and a pathological complete response-adapted strategy in HER2-positive (HER2+) early breast cancer (EBC). Herein, we present RESPONSE, a PHERGain substudy, where clinicopathological and molecular predictors of [18F]FDG-PET disease detection were evaluated. Methods: A total of 500 patients with HER2 + EBC screened in the PHERGain trial with a tumor size > 1.5 cm by magnetic resonance imaging (MRI) were included in the RESPONSE substudy. PET[−] criteria entailed the absence of ≥ 1 breast lesion with maximum standardized uptake value (SUVmax) ≥ 1.5 × SUVmean liver + 2 standard deviation. Among 75 PET[−] patients screened, 21 with SUVmax levels < 2.5 were randomly selected and matched with 21 PET[+] patients with SUVmax levels ≥ 2.5 based on patient characteristics associated with [18F]FDG-PET status. The association between baseline SUVmax and [18F]FDG-PET status ([−] or [+]) with clinicopathological characteristics was assessed. In addition, evaluation of stromal tumor-infiltrating lymphocytes (sTILs) and gene expression analysis using PAM50 and Vantage 3D™ Cancer Metabolism Panel were specifically compared in a matched cohort of excluded and enrolled patients based on the [18F]FDG-PET eligibility criteria. Results: Median SUVmax at baseline was 7.2 (range, 1–39.3). Among all analyzed patients, a higher SUVmax was associated with a higher tumor stage, larger tumor size, lymph node involvement, hormone receptor-negative status, higher HER2 protein expression, increased Ki67 proliferation index, and higher histological grade (p < 0.05). [18F]FDG-PET [−] criteria patients had smaller tumor size (p = 0.014) along with the absence of lymph node involvement and lower histological grade than [18F]FDG-PET [+] patients (p < 0.01). Although no difference in the levels of sTILs was found among 42 matched [18F]FDG-PET [−]/[+] criteria patients (p = 0.73), [18F]FDG-PET [−] criteria patients showed a decreased risk of recurrence (ROR) and a lower proportion of PAM50 HER2-enriched subtype than [18F]FDG-PET[+] patients (p < 0.05). Differences in the expression of genes involved in cancer metabolism were observed between [18F]FDG-PET [−] and [18F]FDG-PET[+] criteria patients. Conclusions: These results highlight the clinical, biological, and metabolic heterogeneity of HER2+ breast cancer, which may facilitate the selection of HER2+ EBC patients likely to benefit from [18F]FDG-PET imaging as a tool to guide therapy. Trial registration: Clinicaltrials.gov; NCT03161353; registration date: May 15, 2017. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors.

Author

Stradella, Agostina, Johnson, Melissa, Goel, Sanjay, Park, Haeseong, Lakhani, Nehal, Arkenau, Hendrik‐Tobias, Galsky, Matthew D., Calvo, Emiliano, Baz, Vicente, Moreno, Victor, Saavedra, Omar, Luen, Stephen J., Mu, Song, Wan, Qiting, Chang, Victoria, Zhang, Wa, and Barve, Minal

Subjects
*TEMOZOLOMIDE, *BRCA genes, *HOMOLOGOUS recombination, *DNA repair, *OVERALL survival
Abstract

Background: Pamiparib is a potent, selective, poly (ADP‐ribose) polymerase 1/2 inhibitor that demonstrates synthetic lethality in cells with breast cancer susceptibility gene mutations or other homologous recombination deficiency. This two‐stage phase 1b study (NCT03150810) assessed pamiparib in combination with temozolomide (TMZ) in adult patients with histologically confirmed locally advanced and metastatic solid tumors. Methods: Oral pamiparib 60 mg was administered twice daily. During the dose‐escalation stage, increasing doses of TMZ (40–120 mg once daily pulsed or 20–40 mg once daily continuous) were administered to determine the recommended dose to be administered in the dose‐expansion stage. The primary objectives were to determine safety and tolerability, maximum tolerated/administered dose, recommended phase 2 dose and schedule, and antitumor activity of pamiparib in combination with TMZ. Pharmacokinetics of pamiparib and TMZ and biomarkers were also assessed. Results: Across stages, 139 patients were treated (dose escalation, n = 66; dose expansion, n = 73). The maximum tolerated dose of TMZ, which was administered during dose expansion, was 7‐day pulsed 60 mg once daily. The most common treatment‐emergent adverse events (TEAEs) were anemia (dose escalation, 56.1%; dose expansion, 63.0%), nausea (dose escalation, 54.5%; dose expansion, 49.3%), and fatigue (dose escalation, 48.5%; dose expansion, 47.9%). In the dose‐escalation stage, four patients experienced dose‐limiting toxicities (three neutropenia and one neutrophil count decreased). No TEAEs considered to be related to study drug treatment resulted in death. Antitumor activity was modest, indicated by confirmed overall response rate (dose escalation, 13.8%; dose expansion, 11.6%), median progression‐free survival (3.7 and 2.8 months), and median overall survival (10.5 and 9.2 months). Administration of combination therapy did not notably impact pamiparib or TMZ pharmacokinetics. Conclusions: Pamiparib in combination with TMZ had a manageable safety profile. Further investigation of the efficacy of this combination in tumor types with specific DNA damage repair deficiencies is warranted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Breast Cancer Patient's Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II–III Disease.

Author

Falo, Catalina, Azcarate, Juan, Fernandez-Gonzalez, Sergi, Perez, Xavier, Petit, Ana, Perez, Héctor, Vethencourt, Andrea, Vazquez, Silvia, Laplana, Maria, Ales, Miriam, Stradella, Agostina, Fullana, Bartomeu, Pla, Maria J., Gumà, Anna, Ortega, Raul, Varela, Mar, Pérez, Diana, Ponton, Jose Luis, Cobo, Sara, and Benitez, Ana

Subjects
THERAPEUTIC use of antineoplastic agents, BREAST tumor treatment, BREAST tumors, CANCER patients, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, CANCER chemotherapy, LONGITUDINAL method, KAPLAN-Meier estimator, LOG-rank test, COMBINED modality therapy, TUMOR classification, SURVIVAL analysis (Biometry), EVALUATION
Abstract

Simple Summary: Neoadjuvant chemotherapy in breast cancer facilitates breast and axillary surgery and offers significant prognostic value. We present a retrospective cohort of 482 stage II and III breast cancer patients treated with neoadjuvant chemotherapy based on anthracycline and taxans, plus antiHER2 in HER2-positive cases. The 10-year estimated disease free survival was 77.3% (95%CI 73.3–81.4%) and the Breast cancer specific survival 83.7% (95%CI 80.3–87.2%). The statistically independent factors related to patient survival were pathology subtype (lobular cancers HR, 4); molecular surrogate subtype (triple negative HR, 4); type of surgery (mastectomy HR, 2), response to chemotherapy (the risk incremented according to the residual cancer burden in 2.2, 4.4 and 8.0 times in I, II and III, respectively) and vascular invasion (HR, 2.4). BRCA carriers presented a longer survival, with an estimated 10 years DDFS of 89.6% vs. 77.2% for non-carriers, p = 0.054. Long-term outcomes after neoadjuvant chemotherapy can help patients and clinicians make well-informed decisions. Introduction: Neoadjuvant chemotherapy in breast cancer offers the possibility to facilitate breast and axillary surgery; it is a test of chemosensibility in vivo with significant prognostic value and may be used to tailor adjuvant treatment according to the response. Material and Methods: A retrospective single-institution cohort of 482 stage II and III breast cancer patients treated with neoadjuvant chemotherapy based on anthracycline and taxans, plus antiHEr2 in Her2-positive cases, was studied. Survival was calculated at 5 and 10 years. Kaplan–Meier curves with a log-rank test were calculated for differences according to age, BRCA status, menopausal status, TNM, pathological and molecular surrogate subtype, 20% TIL cut-off, surgical procedure, response to chemotherapy and the presence of vascular invasion. Results: The pCR rate was 25.3% and was greater in HER2 (51.3%) and TNBC (31.7%) and in BRCA carriers (41.9%). The factors independently related to patient survival were pathology and molecular surrogate subtype, type of surgery, response to NACT and vascular invasion. BRCA status was a protective prognostic factor without reaching statistical significance, with an HR 0.5 (95%CI 0.1–1.4). Mastectomy presented a double risk of distant recurrence compared to breast-conservative surgery (BCS), supporting BCS as a safe option after NACT. After a mean follow-up of 126 (SD 43) months, luminal tumors presented a substantial difference in survival rates calculated at 5 or 10 years (81.2% compared to 74.7%), whereas that for TNBC was 75.3 and 73.5, respectively. The greatest difference was seen according to the response in patients with pCR, who exhibited a 10 years DDFS of 95.5% vs. 72.4% for those patients without pCR, p < 0001. This difference was especially meaningful in TNBC: the 10 years DDFS according to an RCB of 0 to 3 was 100%, 80.6%, 69% and 49.2%, respectively, p < 0001. Patients with a particularly poor prognosis were those with lobular carcinomas, with a 10 years DDFS of 42.9% vs. 79.7% for ductal carcinomas, p = 0.001, and patients with vascular invasion at the surgical specimen, with a 10 years DDFS of 59.2% vs. 83.6% for those patients without vascular invasion, p < 0.001. Remarkably, BRCA carriers presented a longer survival, with an estimated 10 years DDFS of 89.6% vs. 77.2% for non-carriers, p = 0.054. Conclusions: Long-term outcomes after neoadjuvant chemotherapy can help patients and clinicians make well-informed decisions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Immune Cell Associations with Cancer Risk

Author

Palomero, Luis, Galván-Femenía, Ivan, de Cid, Rafael, Espín, Roderic, Barnes, Daniel R., CIMBA, Blommaert, Eline, Gil-Gil, Miguel, Falo, Catalina, Stradella, Agostina, Ouchi, Dan, Roso-Llorach, Albert, Violan, Concepció, Peña-Chilet, María, Dopazo, Joaquín, Extremera, Ana Isabel, García-Valero, Mar, Herranz, Carmen, Mateo, Francesca, Mereu, Elisabetta, Beesley, Jonathan, Chenevix-Trench, Georgia, Roux, Cecilia, Mak, Tak, Brunet, Joan, Hakem, Razq, Gorrini, Chiara, Antoniou, Antonis C., Lázaro, Conxi, and Pujana, Miquel Angel

Published
2020
Full Text
View/download PDF

20. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.

Author

Gion, María, primary, García-Mosquera, Juan José, additional, Pérez-García, José, additional, Peg, Vicente, additional, Ruiz-Borrego, Manuel, additional, Stradella, Agostina, additional, Bermejo, Begoña, additional, Guerrero, José Antonio, additional, López-Montero, Laura, additional, Mancino, Mario, additional, Rodríguez-Morató, José, additional, Antonarelli, Gabriele, additional, Sampayo-Cordero, Miguel, additional, Llombart-Cussac, Antonio, additional, and Cortés, Javier, additional

Published
2024
Full Text
View/download PDF

21. Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?

Author

Garcia-Tejedor, Amparo, Fernandez-Gonzalez, Sergi, Ortega, Raul, Gil-Gil, Miguel, Perez-Montero, Hector, Fernandez-Montolí, Eulalia, Stradella, Agostina, Recalde, Sabela, Soler, Teresa, Petit, Anna, Bajen, Maria Teresa, Benitez, Ana, Guma, Anna, Campos, Miriam, Pla, Maria J., Martinez, Evelyn, Laplana, Maria, Pernas, Sonia, Perez-Sildekova, Diana, Catala, Isabel, Ponce, Jordi, and Falo, Catalina

Published
2021
Full Text
View/download PDF

22. Development of a holistic strategy for the assessment of the quality of life in patients with breast cancer in the different stages of the disease/Desarrollo de una estrategia holistica para la valoracion de la calidad de vida en pacientes con cancer de mama en las distintas etapas de la enfermedad

Author

Gomez-Villarroya, Lorena, Serra-Arumi, Clara, Baez-Saez, Coral, Cervigon, Marisa Mena, Belmonte, Sara Tous, Cortes, Francisca Morey, Bruzos, Eva Rodriguez, Gil, Miguel Gil, Simon, Sonia Pernas, Casado, Andrea Vethencourt, Fernandez, Silvia Vazquez, Stradella, Agostina, Zamora, Catalina Falo, and Guiteras, Antoni Font

Published
2021
Full Text
View/download PDF

24. 638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study

Author

Maia, Ana, primary, Toussaint, Hélène, additional, Magalhaes, Joao Gamelas, additional, Idbaih, Ahmed, additional, Villar, Maria Vieito, additional, Tabatabai, Ghazaleh, additional, Stradella, Agostina, additional, Ghiringhelli, Francois, additional, Burger, Michael C, additional, Mildenberger, Iris, additional, Herrlinger, Ulrich, additional, González, Macarena, additional, Hervieu, Alice, additional, GilMartin, Marta, additional, Renovanz, Mirjam, additional, Touat, Mehdi, additional, Wen, Patrick, additional, Wick, Antje, additional, Bonny, Christophe, additional, Paillarse, Jean-Michel, additional, Reardon, David, additional, Wick, Wolfgang, additional, and Gouttefangeas, Cécile, additional

Published
2023
Full Text
View/download PDF

25. CTIM-25. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: THE PHASE 1/2 EOGBM1-18/ROSALIE STUDY (NCT04116658)

Author

Reardon, David, primary, Idbaih, Ahmed, additional, Vieito, Maria, additional, Ghiringhelli, François, additional, Stradella, Agostina, additional, Tabatabai, Ghazaleh, additional, Burger, Michael C, additional, Mildenberger, Iris, additional, Herrlinger, Ulrich, additional, Wen, Patrick, additional, Touat, Mehdi, additional, Wick, Antje, additional, González, Macarena, additional, Hervieu, Alice, additional, GilMartin, Marta, additional, Renovanz, Mirjam, additional, Gouttefangeas, Cécile, additional, Maia, Ana, additional, Bonny, Christophe, additional, Paillarse, Jean-Michel, additional, Chêne, Laurent, additional, Fagerberg, Jan, additional, and Wick, Wolfgang, additional

Published
2023
Full Text
View/download PDF

26. Supplementary Data1 from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Author

Meric-Bernstam, Funda, primary, Sweis, Randy F., primary, Kasper, Stefan, primary, Hamid, Omid, primary, Bhatia, Shailender, primary, Dummer, Reinhard, primary, Stradella, Agostina, primary, Long, Georgina V., primary, Spreafico, Anna, primary, Shimizu, Toshio, primary, Steeghs, Neeltje, primary, Luke, Jason J., primary, McWhirter, Sarah M., primary, Müller, Thomas, primary, Nair, Nitya, primary, Lewis, Nancy, primary, Chen, Xinhui, primary, Bean, Andrew, primary, Kattenhorn, Lisa, primary, Pelletier, Marc, primary, and Sandhu, Shahneen, primary

Published
2023
Full Text
View/download PDF

28. Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/ HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact.

Author

Garcia-Tejedor, Amparo, primary, Fernandez-Gonzalez, Sergi, additional, Laplana, Maria, additional, Gil-Gil, Miguel, additional, Martinez, Evelyn, additional, Calvo, Iris, additional, Calpelo, Hugo, additional, Ortega, Raul, additional, Petit, Anna, additional, Guma, Anna, additional, Campos, Miriam, additional, Stradella, Agostina, additional, and López-Ojeda, Ana, additional

Published
2023
Full Text
View/download PDF

29. CTIM-17. EO2401 THERAPEUTIC VACCINE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA: PHASE 1/2 ROSALIE STUDY (NCT04116658)

Author

Reardon, David A, primary, Idbaih, Ahmed, additional, Vieito, Maria, additional, Tabatabai, Ghazaleh, additional, Stradella, Agostina, additional, Ghiringhelli, François, additional, Burger, Michael C, additional, Mildenberger, Iris, additional, González, Macarena, additional, Hervieu, Alice, additional, Martin, Marta Gil, additional, Renovanz, Mirjam, additional, Touat, Mehdi, additional, Wen, Patrick Y, additional, Wick, Antje, additional, Gouttefangeas, Cécile, additional, Maia, Ana, additional, Bonny, Christophe, additional, Fagerberg, Jan, additional, and Wick, Wolfgang, additional

Published
2022
Full Text
View/download PDF

30. 642 EO2401 microbiome derived therapeutic vaccine + nivolumab, with/without standard continuous, or low-dose symptom directed, bevacizumab, in recurrent glioblastoma: phase 1–2 EOGBM1–18/ROSALIE study

Author

Reardon, David, primary, Idbaih, Ahmed, additional, Vieito, Maria, additional, Tabatabai, Ghazaleh, additional, Stradella, Agostina, additional, Ghiringhelli, Francois, additional, Burger, Michael, additional, Mildenberger, Iris, additional, Herrlinger, Ulrich, additional, González, Macarena, additional, GilMartin, Marta, additional, Renovanz, Mirjam, additional, Touat, Mehdi, additional, Wen, Patrick, additional, Wick, Antje, additional, Gouttefangeas, Cecile, additional, Maia, Ana, additional, Bonny, Chistophe, additional, Fagerberg, Jan, additional, and Wick, Wolfgang, additional

Published
2022
Full Text
View/download PDF

31. 641 Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab: interim report of the EOGBM1–18/ROSALIE study

Author

Maia, Ana, primary, Toussaint, Hélène, additional, Magalhaes, Joao Gamelas, additional, Reardon, David, additional, IDBAIH, Ahmed, additional, Vieito, Maria, additional, Tabatabai, Ghazaleh, additional, Stradella, Agostina, additional, Ghiringhelli, François, additional, Burger, Michael C, additional, Mildenberger, Iris, additional, Herrlinger, Ulrich, additional, Gonzalez, Macarena, additional, Hervieu, Alice, additional, GilMartin, Marta, additional, Renovanz, Mirjam, additional, Touat, Mehdi, additional, Wen, Patrick Y, additional, Wick, Antje, additional, Chene, Laurent, additional, Gouttefangeas, Cécile, additional, Bonny, Christophe, additional, Fagerberg, Jan, additional, and Wick, Wolfgang, additional

Published
2022
Full Text
View/download PDF

32. Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Author

Meric-Bernstam, Funda, primary, Sweis, Randy F., additional, Kasper, Stefan, additional, Hamid, Omid, additional, Bhatia, Shailender, additional, Dummer, Reinhard, additional, Stradella, Agostina, additional, Long, Georgina V., additional, Spreafico, Anna, additional, Shimizu, Toshio, additional, Steeghs, Neeltje, additional, Luke, Jason J., additional, McWhirter, Sarah M., additional, Müller, Thomas, additional, Nair, Nitya, additional, Lewis, Nancy, additional, Chen, Xinhui, additional, Bean, Andrew, additional, Kattenhorn, Lisa, additional, Pelletier, Marc, additional, and Sandhu, Shahneen, additional

Published
2022
Full Text
View/download PDF

33. Outcomes of patients (pts) treated with novel immunotherapy (IT) agents in phase 1 clinical trials (Ph1-CT) at early lines for advanced disease.

Author

Soto, Juan José, primary, Erasun Lecuona, Carlos, additional, Llop Serna, Sandra, additional, Mulet Margalef, Nuria, additional, Stradella, Agostina, additional, Villanueva, Rafael, additional, Calvo Campos, Mariona, additional, Jove Casulleras, Maria, additional, Cuadra Amor, Carmen, additional, Salazar Soler, Ramon, additional, Gil-Martin, Marta, additional, Martin-Liberal, Juan, additional, and Oliva, Marc, additional

Published
2022
Full Text
View/download PDF

34. EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.

Author

Wick, Wolfgang, primary, Idbaih, Ahmed, additional, Tabatabai, Ghazaleh, additional, Vieito, María, additional, Stradella, Agostina, additional, Ghiringhelli, François, additional, Burger, Michael C., additional, Mildenberger, Iris, additional, Herrlinger, Ulrich, additional, Renovanz, Mirjam, additional, Touat, Mehdi, additional, Wen, Patrick Y., additional, Wick, Antje, additional, Bonny, Christophe, additional, Fagerberg, Jan, additional, Gouttefangeas, Cécile, additional, Maia, Ana, additional, and Reardon, David A., additional

Published
2022
Full Text
View/download PDF

35. Analysis of phase I clinical trials (Ph1-CT) new enrollment patterns in the immuno-oncology era.

Author

Erasun Lecuona, Carlos, primary, Soto, Juan José, additional, Llop Serna, Sandra, additional, Mulet Margalef, Nuria, additional, Stradella, Agostina, additional, Villanueva, Rafael, additional, Calvo Campos, Mariona, additional, Jove Casulleras, Maria, additional, Cuadra Amor, Carmen, additional, Salazar Soler, Ramon, additional, Gil-Martin, Marta, additional, Oliva, Marc, additional, and Martin-Liberal, Juan, additional

Published
2022
Full Text
View/download PDF

36. Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel‐induced peripheral neurotoxicity in breast cancer patients

Author

Karteri, Sofia, primary, Bruna, Jordi, additional, Argyriou, Andreas A., additional, Mariotto, Sara, additional, Velasco, Roser, additional, Alemany, Montse, additional, Kalofonou, Foteini, additional, Alberti, Paola, additional, Dinoto, Alessandro, additional, Velissaris, Dimitrios, additional, Stradella, Agostina, additional, Cavaletti, Guido, additional, Ferrari, Sergio, additional, and Kalofonos, Haralabos P., additional

Published
2022
Full Text
View/download PDF

37. Abstract P2-08-10: First results of the randomized window of opportunity clinical trial D-Biomark: Immunomodulatory effect of denosumab in early breast cancer

Author

Vethencourt, Andrea, primary, Trinidad, Eva M, additional, Petit, Anna, additional, Soler-Monsó, María T, additional, Aleza, Clara Gómez, additional, Urruticochea, Ander, additional, García-Tejedor, Amparo, additional, Martinez, Anna Gumà, additional, Obadia, Veronica, additional, Vazquez, Silvia, additional, Villanueva, Rafael, additional, Fernánez, Adela, additional, Cejuela, Monica, additional, Penabad, Sabela Recalde, additional, Stradella, Agostina, additional, Gil-Gil, Miguel, additional, Pernas, Sonia, additional, Gonzalez-Suarez, Eva, additional, and Falo, Catalina, additional

Published
2022
Full Text
View/download PDF

38. Abstract P5-07-06: Genomic characterization and tumor evolution in matched(primary-relapse)samplesof patients with METAPLASTIC breast cancer

Author

Cejuela, Mónica, primary, Stradella, Agostina, additional, Petit, Anna, additional, Gargallo, Pablo, additional, Bosch, Jan, additional, Carbonell, Paula, additional, Recalde, Sabela, additional, Vethencourt, Andrea, additional, Fernández, Adela, additional, Falo, Catalina, additional, Gil-Gil, Miguel, additional, Vazquez, Silvia, additional, Villanueva, Rafael, additional, Soler, Teresa, additional, Calabria, Inés, additional, and Pernas, Sonia, additional

Published
2022
Full Text
View/download PDF

39. Abstract P1-08-26: Morphologic characterization of tumor-infiltrating lymphocytes and its relation with pathological response in a series of breast cancer patients treated with primary chemotherapy

Author

Falo, Catalina, primary, Azcarate, Juan, additional, Petit, Ana, additional, Vethencourt, Andrea, additional, Gonzalez, Sergi Fernandez, additional, Garcia-Tejedor, Amparo, additional, Vazquez, Silvia, additional, Perez, Hector, additional, Laplana, Maria, additional, Taco, Charo, additional, Guerra, Esther, additional, Guma, Anna, additional, Ortega, Raul, additional, Stradella, Agostina, additional, Recalde, Sabela, additional, Fernandez-Ortega, Adela, additional, Villanueva, Rafael, additional, Perez, F Javier, additional, Pla, M Jesus, additional, Campos, Miriam, additional, Perez, Diana, additional, Fernandez-Montoliu, Eulalia, additional, Obadia, Veronica, additional, Cejuela, Monica, additional, Gil-Gil, Miguel, additional, Pernas, Sonia, additional, Varela, Mar, additional, and Soler-Monzo, Teresa, additional

Published
2022
Full Text
View/download PDF

40. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

Author

Gelmon, Karen A., primary, Fasching, Peter A., additional, Couch, Fergus J., additional, Balmaña, Judith, additional, Delaloge, Suzette, additional, Labidi-Galy, Intidhar, additional, Bennett, James, additional, McCutcheon, Susan, additional, Walker, Graham, additional, O'Shaughnessy, Joyce, additional, Timcheva, Constanta, additional, Tomova, Antoaneta, additional, Eisen, Andrea, additional, Gelmon, Karen, additional, Lemieux, Julie, additional, Bazan, Fernando, additional, Bourgeois, Hugues, additional, Chakiba, Camille, additional, Chehimi, Mohamad, additional, Dalenc, Florence, additional, De La Motte Rouge, Thibault, additional, Frenel, Jean-Sébastien, additional, Gonçalves, Anthony, additional, Hardy-Bessard, Anne Claire, additional, Lamy, Regine, additional, Levy, Christelle, additional, Lortholary, Alain, additional, Mailliez, Audrey, additional, Medioni, Jacques, additional, Patsouris, Anne, additional, Spaeth, Dominique, additional, Teixeira, Luis, additional, Tennevet, Isabelle, additional, Villanueva, Cristian, additional, You, Benoit, additional, Ettl, Johannes, additional, Gerber, Bernd, additional, Hoffmann, Oliver, additional, Park-Simon, Tjoung-Won, additional, Reinisch, Mattea, additional, Tio, Joke, additional, Wimberger, Pauline, additional, Boer, Katalin, additional, Ballestrero, Alberto, additional, Bianchini, Giampaolo, additional, Biganzoli, Laura, additional, Bordonaro, Roberto, additional, Cognetti, Francesco, additional, De Laurentiis, Michelino, additional, De Placido, Sabino, additional, Guarneri, Valentina, additional, Montemurro, Filippo, additional, Naso, Giuseppe, additional, Santoro, Armando, additional, Zamagni, Claudio, additional, Kim, Seung-Jin, additional, Nakamura, Seigo, additional, Chae, Yee Soo, additional, Cho, Eun Kyung, additional, Hyun, Kim Jee, additional, Im, Seock-Ah, additional, Lee, Keun Seok, additional, Park, Yeon Hee, additional, Sohn, Joo Hyuk, additional, Byrski, Tomasz, additional, Huzarski, Tomasz, additional, Kukielka-Budny, Bozena, additional, Nowecki, Zbigniew, additional, Szoszkiewicz, Renata, additional, Tarnawski, Rafal, additional, Dvornichenko, Viktoria, additional, Moiseenko, Fedor, additional, Mukhametshina, Guzel, additional, Poddubskaya, Elena, additional, Popova, Ekaterina, additional, Tarasova, Anna, additional, Vats, Anna, additional, Adamo, Bárbara, additional, Conejero, Raquel Andrés, additional, Torres, Antonio Antón, additional, Gelpi, Judith Balmaña, additional, Fernández, Nieves Díaz, additional, González, Alejandro Falcón, additional, Garcia, Juan, additional, Lorenzo-Lorenzo, Isabel, additional, Antón, Fernando Moreno, additional, Santisteban, Marta, additional, Stradella, Agostina, additional, Huang, Chiun-Sheng, additional, Aksoy, Sercan, additional, Arslan, Cagatay, additional, Artac, Mehmet, additional, Aydiner, Adnan, additional, Ozyilkan, Ozgur, additional, Sezer, Emel, additional, Armstrong, Anne, additional, Barrett, Sophie, additional, Borley, Annabel, additional, Kemp, Zoe, additional, Michie, Caroline, additional, Mukesh, Mukesh, additional, Perren, Timothy, additional, Swampillai, Angela, additional, and Young, Tammy, additional

Published
2021
Full Text
View/download PDF

41. Desarrollo de una estrategia holística para la valoración de la calidad de vida en pacientes con cáncer de mama en las distintas etapas de la enfermedad

Author

Gómez-Villarroya, Lorena, Serra-Arumí, Clara, Báez-Sáez, Coral, Mena Cervigon, Marisa, Tous Belmonte, Sara, Morey Cortes, Francisca, Rodríguez Bruzos, Eva, Gil Gil, Miguel, Pernas Simón, Sonia, Vethencourt Casado, Andrea, Vázquez Fernández, Silvia, Stradella, Agostina, Falo Zamora, Catalina, and Font Guiteras, Antoni

Subjects
Quality of life, multidimensional approach, breast cancer, protocolo, necesidades no atendidas, Calidad de vida, advanced disease, unmet needs, enfoque multidimensional, enfermedad avanzada, protocol, cáncer de mama
Abstract

Introduction: Breast cancer is considered a chronic disease that has considerable impact on the quality of life (QoL) of the patients. Yet, there is not a totally satisfactory evaluation system reflecting the complexity of the breast cancer condition. Furthermore, most instruments are more addressed towards early-stage disease than advanced disease. Objective: To describe the methodology used to measure the QoL of life and coping strategies in a representative group of breast cancer patients including metastatic and non-metastatic patients. Methodology: Prospective study including patients with breast cancer at different stages of the disease recruited at the Medical Oncology Department of the Catalan Oncology Institute (ICO) previous informed consent. A protocol of approximately one hour face-to-face interview is run to collect sociodemographic information and to answer the questions of several QoL scales such as the QLCA-AFex Font, QLQ-C30, QLQ-BR23, HADS, DME, BRCS, MINI-MAC, LOT-R and OE questionnaires, complemented by a semi-structured interview. Results: From June 2017 to March 2020, 257 patients were included in the study. Mean age 57.9 years (SD 10.1), mostly women (98.8%), with children (87.9%) and married (65.4%). According to clinical status 75.5% were non-metastatic and 24.5% metastatic. Protocol compliance was achieved in more than 90% in all questionnaires without differences between metastatic and no metastatic patients. Conclusions: This multidimensional protocol enables us to make an integral assessment of the QoL of the patients and their unmet needs, as well as to reflect the patients’ concerns, both in early and advanced stages of the disease, complementing currently available assessment methods. In the next future a complied questionnaire with the most challenging questions could be developed to be useful as a routine instrument in clinical practice. Introducción: El cáncer de mama es considerado una enfermedad crónica que impacta de modo importante en la calidad de vida (QoL) de las pacientes. En la actualidad no se dispone de un sistema de evaluación totalmente satisfactorio que refleje la complejidad del cáncer de mama. Además, la mayoría de instrumentos están más orientados a la enfermedad en estadios iniciales que a la enfermedad avanzada. Objetivo: Describir la metodología utilizada para evaluar la calidad de vida y las estrategias de afrontamiento en un grupo representativo de cáncer de mama que incluye tanto pacientes metastásicas como no metastásicas. Método: Estudio prospectivo en pacientes con cáncer de mama del Servicio de Oncología Médica del Institut Català d’Oncologia (ICO) en diferentes estadios de la enfermedad, previo consentimiento informado. Se les aplica un protocolo de aproximadamente una hora de entrevista presencial donde se recoge su información sociodemográfica, y se contestan varios cuestionarios de calidad de vida como el cuestionario QLCA-AFex Font, QLQ-C30, QLQ-BR23 HADS, DME, BRCS, MINI-MAC, LOT-R y OE, que se completan con una entrevista semiestructurada. Resultados: De junio de 2017 a marzo de 2020, 257 pacientes han sido incluidas en el estudio. La media de edad es de 57,9 años (SD 10,1), la mayoría son mujeres (98,8%), con hijos (87,9%) y casadas (65,4%). Respecto al estadiaje clínico 75,5% son no-metastásicas y 24,5% metastásicas. El cumplimiento del protocolo se consiguió en más del 90% de los cuestionarios sin diferencias entre pacientes metastásicas y no metastásicas. Conclusión: Este protocolo multidimensional permite hacer una evaluación integral de la calidad de vida, así como reflejar las necesidades no atendidas y las preocupaciones que muestran las pacientes tanto en estadio precoz como avanzado, complementando los sistemas de valoración actualmente disponibles. Después del análisis de los resultados de este estudio sería interesante poder obtener un cuestionario único con las preguntas más relevantes que pudiera ser aplicado a la práctica clínica.

Published
2021

42. Papel de msi, braf y kras como factores pronósticos de supervivencia en el cancer colorrectal : análisis de la experiencia en nuestra institución

Author

Stradella, Agostina, Maroto Rey, José Pablo, Universitat Autònoma de Barcelona. Departament de Medicina, and Universitat Autònoma de Barcelona. Facultat de Medicina

Subjects
Còlon-càncer, Recte-Càncer
Abstract

Con la hipótesis de aclarar el verdadero valor pronóstico de los factores moleculares postulados en el Cáncer colorrectal (CCR) analizamos, en nuestra cohorte de 198 pacientes afectos de CCR con recidiva tras la cirugía inicial, el estado de KRAS, BRAF y MSI. Amb la hipòtesi d'aclarir el veritable valor pronòstic dels factors moleculars postulats en el càncer colorrectal (CCR) analitzem, en la nostre cohort de 198 pacients afectats de CCR amb recidiva després de la cirurgia inicial, l'estat de KRAS, BRAF i MSI.

Published
2021

43. BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort

Author

Rofes, Paula, Del Valle, Jesús, Torres Esquius, Sara, Feliubadaló, Lídia, Stradella, Agostina, Moreno-Cabrera, José Marcos, López-Doriga, Adriana, Munté, Elisabet, de Cid, R., Campos, Olga, Cuesta, Raquel, Teulé, Álex, Grau, Èlia, Sanz, Judit, Capellá, G. (Gabriel), Diez, Orland, Brunet, Joan, Balmaña Gelpí, Judith, Lázaro, Conxi, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Rofes P, Del Valle J, Feliubadaló L, Moreno-Cabrera JM] Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet de Llobregat, Spain. Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L’Hospitalet de Llobregat, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. [Torres-Esquius S, Balmaña J] Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Stradella A] Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, L’Hospitalet de Llobregat, Spain. Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L’Hospitalet de Llobregat, Spain. Medical Oncology Department, Catalan Institute of Oncology, IDIBELL, L’Hospitalet de Llobregat, Spain. [Díez O] Institut Català de la Salut, Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Hereditary Cancer Genetics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, lcsh:QH426-470, Moderate cancer risk, Hereditary breast and ovarian cancer, Càncer d'ovari, Genetic Phenomena::Genotype::Genetic Predisposition to Disease [PHENOMENA AND PROCESSES], Ovaris - Càncer - Aspectes genètics, hereditary breast and ovarian cancer, Germline, Article, Càncer de mama, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, breast cancer, Triple-negative breast cancer, Ovarian cancer, Internal medicine, Genetics, medicine, BARD1, Genetics (clinical), Genetic testing, fenómenos genéticos::genotipo::predisposición genética a la enfermedad [FENÓMENOS Y PROCESOS], moderate cancer risk, medicine.diagnostic_test, business.industry, Odds ratio, medicine.disease, Penetrance, neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos [ENFERMEDADES], lcsh:Genetics, 030104 developmental biology, Neoplasms::Neoplasms::Neoplasms::Neoplastic Syndromes, Hereditary::Hereditary Breast and Ovarian Cancer Syndrome [DISEASES], ovarian cancer, 030220 oncology & carcinogenesis, Cohort, Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms [DISEASES], triple-negative breast cancer, Mama - Càncer - Aspectes genètics, neoplasias::neoplasias::neoplasias::síndromes neoplásicos hereditarios::síndrome hereditario de cáncer de mama y ovario [ENFERMEDADES], business
Abstract

Only a small fraction of hereditary breast and/or ovarian cancer (HBOC) cases are caused by germline variants in the high-penetrance breast cancer 1 and 2 genes (BRCA1 and BRCA2). BRCA1-associated ring domain 1 (BARD1), nuclear partner of BRCA1, has been suggested as a potential HBOC risk gene, although its prevalence and penetrance are variable according to populations and type of tumor. We aimed to investigate the prevalence of BARD1 truncating variants in a cohort of patients with clinical suspicion of HBOC. A comprehensive BARD1 screening by multigene panel analysis was performed in 4015 unrelated patients according to our regional guidelines for genetic testing in hereditary cancer. In addition, 51,202 Genome Aggregation Database (gnomAD) non-Finnish, non-cancer European individuals were used as a control population. In our patient cohort, we identified 19 patients with heterozygous BARD1 truncating variants (0.47%), whereas the frequency observed in the gnomAD controls was 0.12%. We found a statistically significant association of truncating BARD1 variants with overall risk (odds ratio (OR) = 3.78, CI = 2.10&ndash, 6.48, p = 1.16 &times, 10&minus, 5). This association remained significant in the hereditary breast cancer (HBC) group (OR = 4.18, 7.70, p = 5.45 &times, 5). Furthermore, deleterious BARD1 variants were enriched among triple-negative BC patients (OR = 5.40, CI = 1.77&ndash, 18.15, p = 0.001) compared to other BC subtypes. Our results support the role of BARD1 as a moderate penetrance BC predisposing gene and highlight a stronger association with triple-negative tumors.

Published
2021

44. Development of a holistic strategy for the assessment of the quality of life in patients with breast cancer in the different stages of the disease

Author

Gómez-Villarroya, Lorena, Serra-Arumí, Clara, Báez-Sáez, Coral, Mena Cervigon, Marisa, Tous Belmonte, Sara, Morey Cortes, Francisca, Rodríguez Bruzos, Eva, Gil Gil, Miguel, Pernas Simón, Sonia, Vethencourt Casado, Andrea, Vázquez Fernández, Silvia, Stradella, Agostina, Falo Zamora, Catalina, Font Guiteras, Antoni, Gómez-Villarroya, Lorena, Serra-Arumí, Clara, Báez-Sáez, Coral, Mena Cervigon, Marisa, Tous Belmonte, Sara, Morey Cortes, Francisca, Rodríguez Bruzos, Eva, Gil Gil, Miguel, Pernas Simón, Sonia, Vethencourt Casado, Andrea, Vázquez Fernández, Silvia, Stradella, Agostina, Falo Zamora, Catalina, and Font Guiteras, Antoni

Abstract

Introduction: Breast cancer is considered a chronic disease that has considerable impact on the quality of life (QoL) of the patients. Yet, there is not a totally satisfactory evaluation system reflecting the complexity of the breast cancer condition. Furthermore, most instruments are more addressed towards early-stage disease than advanced disease. Objective: To describe the methodology used to measure the QoL of life and coping strategies in a representative group of breast cancer patients including metastatic and non-metastatic patients. Methodology: Prospective study including patients with breast cancer at different stages of the disease recruited at the Medical Oncology Department of the Catalan Oncology Institute (ICO) previous informed consent. A protocol of approximately one hour face-to-face interview is run to collect sociodemographic information and to answer the questions of several QoL scales such as the QLCA-AFex Font, QLQ-C30, QLQ-BR23, HADS, DME, BRCS, MINI-MAC, LOT-R and OE questionnaires, complemented by a semi-structured interview. Results: From June 2017 to March 2020, 257 patients were included in the study. Mean age 57.9 years (SD 10.1), mostly women (98.8%), with children (87.9%) and married (65.4%). According to clinical status 75.5% were non-metastatic and 24.5% metastatic. Protocol compliance was achieved in more than 90% in all questionnaires without differences between metastatic and no metastatic patients. Conclusions: This multidimensional protocol enables us to make an integral assessment of the QoL of the patients and their unmet needs, as well as to reflect the patients’ concerns, both in early and advanced stages of the disease, complementing currently available assessment methods. In the next future a complied questionnaire with the most challenging questions could be developed to be useful as a routine instrument in clinical practice., Introducción: El cáncer de mama es considerado una enfermedad crónica que impacta de modo importante en la calidad de vida (QoL) de las pacientes. En la actualidad no se dispone de un sistema de evaluación totalmente satisfactorio que refleje la complejidad del cáncer de mama. Además, la mayoría de instrumentos están más orientados a la enfermedad en estadios iniciales que a la enfermedad avanzada. Objetivo: Describir la metodología utilizada para evaluar la calidad de vida y las estrategias de afrontamiento en un grupo representativo de cáncer de mama que incluye tanto pacientes metastásicas como no metastásicas. Método: Estudio prospectivo en pacientes con cáncer de mama del Servicio de Oncología Médica del Institut Català d’Oncologia (ICO) en diferentes estadios de la enfermedad, previo consentimiento informado. Se les aplica un protocolo de aproximadamente una hora de entrevista presencial donde se recoge su información sociodemográfica, y se contestan varios cuestionarios de calidad de vida como el cuestionario QLCA-AFex Font, QLQ-C30, QLQ-BR23 HADS, DME, BRCS, MINI-MAC, LOT-R y OE, que se completan con una entrevista semiestructurada. Resultados: De junio de 2017 a marzo de 2020, 257 pacientes han sido incluidas en el estudio. La media de edad es de 57,9 años (SD 10,1), la mayoría son mujeres (98,8%), con hijos (87,9%) y casadas (65,4%). Respecto al estadiaje clínico 75,5% son no-metastásicas y 24,5% metastásicas. El cumplimiento del protocolo se consiguió en más del 90% de los cuestionarios sin diferencias entre pacientes metastásicas y no metastásicas. Conclusión: Este protocolo multidimensional permite hacer una evaluación integral de la calidad de vida, así como reflejar las necesidades no atendidas y las preocupaciones que muestran las pacientes tanto en estadio precoz como avanzado, complementando los sistemas de valoración actualmente disponibles. Después del análisis de los resultados de este estudio sería interesante poder obtener un cuestionario únic

Published
2021

46. A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease.

Author

Yee, Douglas, primary, LoRusso, Patricia, additional, Sablin, Marie Paule, additional, Prat, Aleix, additional, Stradella, Agostina, additional, Utriainen, Meri, additional, Oliveira, Mafalda, additional, Yonemori, Kan, additional, Naito, Yoichi, additional, Hardebeck, Molly Catherine, additional, Puig, Marta, additional, Hu, Joy, additional, Biyukov, Tsvetan Nikolov, additional, and Iwata, Hiroji, additional

Published
2021
Full Text
View/download PDF

47. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

Author

Patel, Vivek L., Busch, Evan L., Friebel, Tara M., Cronin, Angel, Leslie, Goska, McGuffog, Lesley, Adlard, Julian, Agata, Simona, Agnarsson, Bjarni A., Ahmed, Munaza, Aittomaki, Kristiina, Alducci, Elisa, Andrulis, Irene L., Arason, Adalgeir, Arnold, Norbert, Artioli, Grazia, Arver, Brita, Auber, Bernd, Azzollini, Jacopo, Balmana, Judith, Barkardottir, Rosa B., Barnes, Daniel R., Barroso, Alicia, Barrowdale, Daniel, Belotti, Muriel, Benitez, Javier, Bertelsen, Brigitte, Blok, Marinus J., Bodrogi, Istvan, Bonadona, Valerie, Bonanni, Bernardo, Bondavalli, Davide, Boonen, Susanne E., Borde, Julika, Borg, Ake, Bradbury, Angela R., Brady, Angela, Brewer, Carole, Brunet, Joan, Buecher, Bruno, Buys, Saundra S., Cabezas-Camarero, Santiago, Caldes, Trinidad, Caliebe, Almuth, Caligo, Maria A., Calvello, Mariarosaria, Campbell, Ian G., Carnevali, Ileana, Carrasco, Estela, Chan, Tsun L., Chu, Annie T. W., Chung, Wendy K., Claes, Kathleen B. M., Cook, Jackie, Cortesi, Laura, Couch, Fergus J., Daly, Mary B., Damante, Giuseppe, Darder, Esther, Davidson, Rosemarie, de la Hoya, Miguel, Della Puppa, Lara, Dennis, Joe, Diez, Orland, Ding, Yuan Chun, Ditsch, Nina, Domchek, Susan M., Donaldson, Alan, Dworniczak, Bernd, Easton, Douglas F., Eccles, Diana M., Eeles, Rosalind A., Ehrencrona, Hans, Ejlertsen, Bent, Engel, Christoph, Evans, D. Gareth, Faivre, Laurence, Faust, Ulrike, Feliubadalo, Lidia, Foretova, Lenka, Fostira, Florentia, Fountzilas, George, Frost, Debra, Garcia-Barberan, Vanesa, Garre, Pilar, Gauthier-Villars, Marion, Geczi, Lajos, Gehrig, Andrea, Gerdes, Anne-Marie, Gesta, Paul, Giannini, Giuseppe, Glendon, Gord, Godwin, Andrew K., Goldgar, David E., Greene, Mark H., Gutierrez-Barrera, Angelica M., Hahnen, Eric, Hamann, Ute, Hauke, Jan, Herold, Natalie, Hogervorst, Frans B. L., Honisch, Ellen, Hopper, John L., Hulick, Peter J., Izatt, Louise, Jager, Agnes, James, Paul, Janavicius, Ramunas, Jensen, Uffe Birk, Jensen, Thomas Dyrso, Johannsson, Oskar Th, John, Esther M., Joseph, Vijai, Kang, Eunyoung, Kast, Karin, Kiiski, Johanna, I, Kim, Sung-Won, Kim, Zisun, Ko, Kwang-Pil, Konstantopoulou, Irene, Kramer, Gero, Krogh, Lotte, Kruse, Torben A., Kwong, Ava, Larsen, Mirjam, Lasset, Christine, Lautrup, Charlotte, Lazaro, Conxi, Lee, Jihyoun, Lee, Jong Won, Lee, Min Hyuk, Lemke, Johannes, Lesueur, Fabienne, Liljegren, Annelie, Lindblom, Annika, Llovet, Patricia, Lopez-Fernandez, Adria, Lopez-Perolio, Irene, Lorca, Victor, Loud, Jennifer T., Ma, Edmond S. K., Mai, Phuong L., Manoukian, Siranoush, Mari, Veronique, Martin, Lynn, Matricardi, Laura, Mebirouk, Noura, Medici, Veronica, Meijers-Heijboer, Hanne E. J., Meindl, Alfons, Mensenkamp, Arjen R., Miller, Clare, Gomes, Denise Molina, Montagna, Marco, Mooij, Thea M., Moserle, Lidia, Mouret-Fourme, Emmanuelle, Mulligan, Anna Marie, Nathanson, Katherine L., Navratilova, Marie, Nevanlinna, Heli, Niederacher, Dieter, Nielsen, Finn C. Cilius, Nikitina-Zake, Liene, Offit, Kenneth, Olah, Edith, Olopade, Olufunmilayo, I, Ong, Kai-Ren, Osorio, Ana, Ott, Claus-Eric, Palli, Domenico, Park, Sue K., Parsons, Michael T., Pedersen, Inge Sokilde, Peissel, Bernard, Peixoto, Ana, Perez-Segura, Pedro, Peterlongo, Paolo, Petersen, Annabeth Hogh, Porteous, Mary E., Angel Pujana, Miguel, Radice, Paolo, Ramser, Juliane, Rantala, Johanna, Rashid, Muhammad U., Rhiem, Kerstin, Rizzolo, Piera, Robson, Mark E., Rookus, Matti A., Rossing, Caroline M., Ruddy, Kathryn J., Santos, Catarina, Saule, Claire, Scarpitta, Rosa, Schmutzler, Rita K., Schuster, Helene, Senter, Leigha, Seynaeve, Caroline M., Shah, Payal D., Sharma, Priyanka, Shin, Vivian Y., Silvestri, Valentina, Simard, Jacques, Singer, Christian F., Skytte, Anne-Bine, Snape, Katie, Solano, Angela R., Soucy, Penny, Southey, Melissa C., Spurdle, Amanda B., Steele, Linda, Steinemann, Doris, Stoppa-Lyonnet, Dominique, Stradella, Agostina, Sunde, Lone, Sutter, Christian, Tan, Yen Y., Teixeira, Manuel R., Teo, Soo Hwang, Thomassen, Mads, Tibiletti, Maria Grazia, Tischkowitz, Marc, Tognazzo, Silvia, Toland, Amanda E., Tommasi, Stefania, Torres, Diana, Toss, Angela, Trainer, Alison H., Tung, Nadine, van Asperen, Christi J., van der Baan, Frederieke H., van der Kolk, Lizet E., van der Luijt, Rob B., van Hest, Liselotte P., Varesco, Liliana, Varon-Mateeva, Raymonda, Viel, Alessandra, Vierstrate, Jeroen, Villa, Roberta, von Wachenfeldt, Anna, Wagner, Philipp, Wang-Gohrke, Shan, Wappenschmidt, Barbara, Weitzel, Jeffrey N., Wieme, Greet, Yadav, Siddhartha, Yannoukakos, Drakoulis, Yoon, Sook-Yee, Zanzottera, Cristina, Zorn, Kristin K., D'Amico, Anthony, V, Freedman, Matthew L., Pomerantz, Mark M., Chenevix-Trench, Georgia, Antoniou, Antonis C., Neuhausen, Susan L., Ottini, Laura, Nielsen, Henriette Roed, Rebbeck, Timothy R., Patel, Vivek L., Busch, Evan L., Friebel, Tara M., Cronin, Angel, Leslie, Goska, McGuffog, Lesley, Adlard, Julian, Agata, Simona, Agnarsson, Bjarni A., Ahmed, Munaza, Aittomaki, Kristiina, Alducci, Elisa, Andrulis, Irene L., Arason, Adalgeir, Arnold, Norbert, Artioli, Grazia, Arver, Brita, Auber, Bernd, Azzollini, Jacopo, Balmana, Judith, Barkardottir, Rosa B., Barnes, Daniel R., Barroso, Alicia, Barrowdale, Daniel, Belotti, Muriel, Benitez, Javier, Bertelsen, Brigitte, Blok, Marinus J., Bodrogi, Istvan, Bonadona, Valerie, Bonanni, Bernardo, Bondavalli, Davide, Boonen, Susanne E., Borde, Julika, Borg, Ake, Bradbury, Angela R., Brady, Angela, Brewer, Carole, Brunet, Joan, Buecher, Bruno, Buys, Saundra S., Cabezas-Camarero, Santiago, Caldes, Trinidad, Caliebe, Almuth, Caligo, Maria A., Calvello, Mariarosaria, Campbell, Ian G., Carnevali, Ileana, Carrasco, Estela, Chan, Tsun L., Chu, Annie T. W., Chung, Wendy K., Claes, Kathleen B. M., Cook, Jackie, Cortesi, Laura, Couch, Fergus J., Daly, Mary B., Damante, Giuseppe, Darder, Esther, Davidson, Rosemarie, de la Hoya, Miguel, Della Puppa, Lara, Dennis, Joe, Diez, Orland, Ding, Yuan Chun, Ditsch, Nina, Domchek, Susan M., Donaldson, Alan, Dworniczak, Bernd, Easton, Douglas F., Eccles, Diana M., Eeles, Rosalind A., Ehrencrona, Hans, Ejlertsen, Bent, Engel, Christoph, Evans, D. Gareth, Faivre, Laurence, Faust, Ulrike, Feliubadalo, Lidia, Foretova, Lenka, Fostira, Florentia, Fountzilas, George, Frost, Debra, Garcia-Barberan, Vanesa, Garre, Pilar, Gauthier-Villars, Marion, Geczi, Lajos, Gehrig, Andrea, Gerdes, Anne-Marie, Gesta, Paul, Giannini, Giuseppe, Glendon, Gord, Godwin, Andrew K., Goldgar, David E., Greene, Mark H., Gutierrez-Barrera, Angelica M., Hahnen, Eric, Hamann, Ute, Hauke, Jan, Herold, Natalie, Hogervorst, Frans B. L., Honisch, Ellen, Hopper, John L., Hulick, Peter J., Izatt, Louise, Jager, Agnes, James, Paul, Janavicius, Ramunas, Jensen, Uffe Birk, Jensen, Thomas Dyrso, Johannsson, Oskar Th, John, Esther M., Joseph, Vijai, Kang, Eunyoung, Kast, Karin, Kiiski, Johanna, I, Kim, Sung-Won, Kim, Zisun, Ko, Kwang-Pil, Konstantopoulou, Irene, Kramer, Gero, Krogh, Lotte, Kruse, Torben A., Kwong, Ava, Larsen, Mirjam, Lasset, Christine, Lautrup, Charlotte, Lazaro, Conxi, Lee, Jihyoun, Lee, Jong Won, Lee, Min Hyuk, Lemke, Johannes, Lesueur, Fabienne, Liljegren, Annelie, Lindblom, Annika, Llovet, Patricia, Lopez-Fernandez, Adria, Lopez-Perolio, Irene, Lorca, Victor, Loud, Jennifer T., Ma, Edmond S. K., Mai, Phuong L., Manoukian, Siranoush, Mari, Veronique, Martin, Lynn, Matricardi, Laura, Mebirouk, Noura, Medici, Veronica, Meijers-Heijboer, Hanne E. J., Meindl, Alfons, Mensenkamp, Arjen R., Miller, Clare, Gomes, Denise Molina, Montagna, Marco, Mooij, Thea M., Moserle, Lidia, Mouret-Fourme, Emmanuelle, Mulligan, Anna Marie, Nathanson, Katherine L., Navratilova, Marie, Nevanlinna, Heli, Niederacher, Dieter, Nielsen, Finn C. Cilius, Nikitina-Zake, Liene, Offit, Kenneth, Olah, Edith, Olopade, Olufunmilayo, I, Ong, Kai-Ren, Osorio, Ana, Ott, Claus-Eric, Palli, Domenico, Park, Sue K., Parsons, Michael T., Pedersen, Inge Sokilde, Peissel, Bernard, Peixoto, Ana, Perez-Segura, Pedro, Peterlongo, Paolo, Petersen, Annabeth Hogh, Porteous, Mary E., Angel Pujana, Miguel, Radice, Paolo, Ramser, Juliane, Rantala, Johanna, Rashid, Muhammad U., Rhiem, Kerstin, Rizzolo, Piera, Robson, Mark E., Rookus, Matti A., Rossing, Caroline M., Ruddy, Kathryn J., Santos, Catarina, Saule, Claire, Scarpitta, Rosa, Schmutzler, Rita K., Schuster, Helene, Senter, Leigha, Seynaeve, Caroline M., Shah, Payal D., Sharma, Priyanka, Shin, Vivian Y., Silvestri, Valentina, Simard, Jacques, Singer, Christian F., Skytte, Anne-Bine, Snape, Katie, Solano, Angela R., Soucy, Penny, Southey, Melissa C., Spurdle, Amanda B., Steele, Linda, Steinemann, Doris, Stoppa-Lyonnet, Dominique, Stradella, Agostina, Sunde, Lone, Sutter, Christian, Tan, Yen Y., Teixeira, Manuel R., Teo, Soo Hwang, Thomassen, Mads, Tibiletti, Maria Grazia, Tischkowitz, Marc, Tognazzo, Silvia, Toland, Amanda E., Tommasi, Stefania, Torres, Diana, Toss, Angela, Trainer, Alison H., Tung, Nadine, van Asperen, Christi J., van der Baan, Frederieke H., van der Kolk, Lizet E., van der Luijt, Rob B., van Hest, Liselotte P., Varesco, Liliana, Varon-Mateeva, Raymonda, Viel, Alessandra, Vierstrate, Jeroen, Villa, Roberta, von Wachenfeldt, Anna, Wagner, Philipp, Wang-Gohrke, Shan, Wappenschmidt, Barbara, Weitzel, Jeffrey N., Wieme, Greet, Yadav, Siddhartha, Yannoukakos, Drakoulis, Yoon, Sook-Yee, Zanzottera, Cristina, Zorn, Kristin K., D'Amico, Anthony, V, Freedman, Matthew L., Pomerantz, Mark M., Chenevix-Trench, Georgia, Antoniou, Antonis C., Neuhausen, Susan L., Ottini, Laura, Nielsen, Henriette Roed, and Rebbeck, Timothy R.

Abstract

Pathogenic sequence variants (PSV) in BRCA1 or BRCA2 (BRCA1/2) are associated with increased risk and severity of prostate cancer. Weevaluated whether PSVs inBRCA1/2 were associated with risk of overall prostate cancer or high grade (Gleason 8+) prostate cancer using an international sample of 65 BRCA1 and 171 BRCA2 male PSV carriers with prostate cancer, and 3,388 BRCA1 and 2,880 BRCA2 male PSV carriers without prostate cancer. PSVs in the 30 region of BRCA2 (c.7914+) were significantly associated with elevated risk of prostate cancer compared with reference bin c.1001c.7913 [HR = 1.78; 95% confidence interval (CI), 1.25-2.52; P = 0.001], as well as elevated risk of Gleason 8+ prostate cancer (HR = 3.11; 95% CI, 1.63-5.95; P = 0.001). c.756-c.1000 was also associated with elevated prostate cancer risk (HR = 2.83; 95% CI, 1.71-4.68; P = 0.00004) and elevated risk of Gleason 8+prostate cancer (HR = 4.95; 95% CI, 2.12-11.54; P = 0.0002). No genotype-phenotype associations were detected for PSVs in BRCA1. These results demonstrate that specific BRCA2 PSVs may be associated with elevated risk of developing aggressive prostate cancer. Significance: Aggressive prostate cancer risk in BRCA2 mutation carriers may vary according to the specific BRCA2 mutation inherited by the at-risk individual.

Published
2020

48. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

Author

Patel, Vivek L, Busch, Evan L, Friebel, Tara M, Cronin, Angel, Leslie, Goska, McGuffog, Lesley, Adlard, Julian, Agata, Simona, Agnarsson, Bjarni A, Ahmed, Munaza, Aittomäki, Kristiina, Alducci, Elisa, Andrulis, Irene L, Arason, Adalgeir, Arnold, Norbert, Artioli, Grazia, Arver, Brita, Auber, Bernd, Azzollini, Jacopo, Balmaña, Judith, Barkardottir, Rosa B, Barnes, Daniel R, Barroso, Alicia, Barrowdale, Daniel, Belotti, Muriel, Benitez, Javier, Bertelsen, Birgitte, Blok, Marinus J, Bodrogi, Istvan, Bonadona, Valérie, Bonanni, Bernardo, Bondavalli, Davide, Boonen, Susanne E, Borde, Julika, Borg, Ake, Bradbury, Angela R, Brady, Angela, Brewer, Carole, Brunet, Joan, Buecher, Bruno, Buys, Saundra S, Cabezas-Camarero, Santiago, Caldés, Trinidad, Caliebe, Almuth, Caligo, Maria A, Calvello, Mariarosaria, Campbell, Ian G, Carnevali, Ileana, Carrasco, Estela, Chan, Tsun L, Chu, Annie T W, Chung, Wendy K, Claes, Kathleen B M, Collaborators, Gemo Study, Collaborators, Embrace, Cook, Jackie, Cortesi, Laura, Couch, Fergus J, Daly, Mary B, Damante, Giuseppe, Darder, Esther, Davidson, Rosemarie, de la Hoya, Miguel, Puppa, Lara Della, Dennis, Joe, Díez, Orland, Ding, Yuan Chun, Ditsch, Nina, Domchek, Susan M, Donaldson, Alan, Dworniczak, Bernd, Easton, Douglas F, Eccles, Diana M, Eeles, Rosalind A, Ehrencrona, Hans, Ejlertsen, Bent, Engel, Christoph, Evans, D Gareth, Faivre, Laurence, Faust, Ulrike, Feliubadaló, Lídia, Foretova, Lenka, Fostira, Florentia, Fountzilas, George, Frost, Debra, García-Barberán, Vanesa, Garre, Pilar, Gauthier-Villars, Marion, Géczi, Lajos, Gehrig, Andrea, Gerdes, Anne-Marie, Gesta, Paul, Giannini, Giuseppe, Glendon, Gord, Godwin, Andrew K, Goldgar, David E, Greene, Mark H, Gutierrez-Barrera, Angelica M, Hahnen, Eric, Hamann, Ute, Hauke, Jan, Herold, Natalie, Hogervorst, Frans B L, Honisch, Ellen, Hopper, John L, Hulick, Peter J, Investigators, KConFab, Investigators, Hebon, Izatt, Louise, Jager, Agnes, James, Paul, Janavicius, Ramunas, Jensen, Uffe Birk, Jensen, Thomas Dyrso, Johannsson, Oskar Th, John, Esther M, Joseph, Vijai, Kang, Eunyoung, Kast, Karin, Kiiski, Johanna I, Kim, Sung-Won, Kim, Zisun, Ko, Kwang-Pil, Konstantopoulou, Irene, Kramer, Gero, Krogh, Lotte, Kruse, Torben A, Kwong, Ava, Larsen, Mirjam, Lasset, Christine, Lautrup, Charlotte, Lazaro, Conxi, Lee, Jihyoun, Lee, Jong Won, Lee, Min Hyuk, Lemke, Johannes, Lesueur, Fabienne, Liljegren, Annelie, Lindblom, Annika, Llovet, Patricia, Lopez-Fernández, Adria, Lopez-Perolio, Irene, Lorca, Victor, Loud, Jennifer T, Ma, Edmond S K, Mai, Phuong L, Manoukian, Siranoush, Mari, Veronique, Martin, Lynn, Matricardi, Laura, Mebirouk, Noura, Medici, Veronica, Meijers-Heijboer, Hanne E J, Meindl, Alfons, Mensenkamp, Arjen R, Miller, Clare, Gomes, Denise Molina, Montagna, Marco, Mooij, Thea M, Moserle, Lidia, Mouret-Fourme, Emmanuelle, Mulligan, Anna Marie, Nathanson, Katherine L, Navratilova, Marie, Nevanlinna, Heli, Niederacher, Dieter, Nielsen, Finn C Cilius, Nikitina-Zake, Liene, Offit, Kenneth, Olah, Edith, Olopade, Olufunmilayo I, Ong, Kai-Ren, Osorio, Ana, Ott, Claus-Eric, Palli, Domenico, Park, Sue K, Parsons, Michael T, Pedersen, Inge Sokilde, Peissel, Bernard, Peixoto, Ana, Pérez-Segura, Pedro, Peterlongo, Paolo, Petersen, Annabeth Høgh, Porteous, Mary E, Pujana, Miguel Angel, Radice, Paolo, Ramser, Juliane, Rantala, Johanna, Rashid, Muhammad U, Rhiem, Kerstin, Rizzolo, Piera, Robson, Mark E, Rookus, Matti A, Rossing, Caroline M, Ruddy, Kathryn J, Santos, Catarina, Saule, Claire, Scarpitta, Rosa, Schmutzler, Rita K, Schuster, Hélène, Senter, Leigha, Seynaeve, Caroline M, Shah, Payal D, Sharma, Priyanka, Shin, Vivian Y, Silvestri, Valentina, Simard, Jacques, Singer, Christian F, Skytte, Anne-Bine, Snape, Katie, Solano, Angela R, Soucy, Penny, Southey, Melissa C, Spurdle, Amanda B, Steele, Linda, Steinemann, Doris, Stoppa-Lyonnet, Dominique, Stradella, Agostina, Sunde, Lone, Sutter, Christian, Tan, Yen Y, Teixeira, Manuel R, Teo, Soo Hwang, Thomassen, Mads, Tibiletti, Maria Grazia, Tischkowitz, Marc, Tognazzo, Silvia, Toland, Amanda E, Tommasi, Stefania, Torres, Diana, Toss, Angela, Trainer, Alison H, Tung, Nadine, van Asperen, Christi J, van der Baan, Frederieke H, van der Kolk, Lizet E, van der Luijt, Rob B, van Hest, Liselotte P, Varesco, Liliana, Varon-Mateeva, Raymonda, Viel, Alessandra, Vierstraete, Jeroen, Villa, Roberta, von Wachenfeldt, Anna, Wagner, Philipp, Wang-Gohrke, Shan, Wappenschmidt, Barbara, Weitzel, Jeffrey N, Wieme, Greet, Yadav, Siddhartha, Yannoukakos, Drakoulis, Yoon, Sook-Yee, Zanzottera, Cristina, Zorn, Kristin K, D'Amico, Anthony V, Freedman, Matthew L, Pomerantz, Mark M, Chenevix-Trench, Georgia, Antoniou, Antonis C, Neuhausen, Susan L, Ottini, Laura, Nielsen, Henriette Roed, Rebbeck, Timothy R, Patel, Vivek L, Busch, Evan L, Friebel, Tara M, Cronin, Angel, Leslie, Goska, McGuffog, Lesley, Adlard, Julian, Agata, Simona, Agnarsson, Bjarni A, Ahmed, Munaza, Aittomäki, Kristiina, Alducci, Elisa, Andrulis, Irene L, Arason, Adalgeir, Arnold, Norbert, Artioli, Grazia, Arver, Brita, Auber, Bernd, Azzollini, Jacopo, Balmaña, Judith, Barkardottir, Rosa B, Barnes, Daniel R, Barroso, Alicia, Barrowdale, Daniel, Belotti, Muriel, Benitez, Javier, Bertelsen, Birgitte, Blok, Marinus J, Bodrogi, Istvan, Bonadona, Valérie, Bonanni, Bernardo, Bondavalli, Davide, Boonen, Susanne E, Borde, Julika, Borg, Ake, Bradbury, Angela R, Brady, Angela, Brewer, Carole, Brunet, Joan, Buecher, Bruno, Buys, Saundra S, Cabezas-Camarero, Santiago, Caldés, Trinidad, Caliebe, Almuth, Caligo, Maria A, Calvello, Mariarosaria, Campbell, Ian G, Carnevali, Ileana, Carrasco, Estela, Chan, Tsun L, Chu, Annie T W, Chung, Wendy K, Claes, Kathleen B M, Collaborators, Gemo Study, Collaborators, Embrace, Cook, Jackie, Cortesi, Laura, Couch, Fergus J, Daly, Mary B, Damante, Giuseppe, Darder, Esther, Davidson, Rosemarie, de la Hoya, Miguel, Puppa, Lara Della, Dennis, Joe, Díez, Orland, Ding, Yuan Chun, Ditsch, Nina, Domchek, Susan M, Donaldson, Alan, Dworniczak, Bernd, Easton, Douglas F, Eccles, Diana M, Eeles, Rosalind A, Ehrencrona, Hans, Ejlertsen, Bent, Engel, Christoph, Evans, D Gareth, Faivre, Laurence, Faust, Ulrike, Feliubadaló, Lídia, Foretova, Lenka, Fostira, Florentia, Fountzilas, George, Frost, Debra, García-Barberán, Vanesa, Garre, Pilar, Gauthier-Villars, Marion, Géczi, Lajos, Gehrig, Andrea, Gerdes, Anne-Marie, Gesta, Paul, Giannini, Giuseppe, Glendon, Gord, Godwin, Andrew K, Goldgar, David E, Greene, Mark H, Gutierrez-Barrera, Angelica M, Hahnen, Eric, Hamann, Ute, Hauke, Jan, Herold, Natalie, Hogervorst, Frans B L, Honisch, Ellen, Hopper, John L, Hulick, Peter J, Investigators, KConFab, Investigators, Hebon, Izatt, Louise, Jager, Agnes, James, Paul, Janavicius, Ramunas, Jensen, Uffe Birk, Jensen, Thomas Dyrso, Johannsson, Oskar Th, John, Esther M, Joseph, Vijai, Kang, Eunyoung, Kast, Karin, Kiiski, Johanna I, Kim, Sung-Won, Kim, Zisun, Ko, Kwang-Pil, Konstantopoulou, Irene, Kramer, Gero, Krogh, Lotte, Kruse, Torben A, Kwong, Ava, Larsen, Mirjam, Lasset, Christine, Lautrup, Charlotte, Lazaro, Conxi, Lee, Jihyoun, Lee, Jong Won, Lee, Min Hyuk, Lemke, Johannes, Lesueur, Fabienne, Liljegren, Annelie, Lindblom, Annika, Llovet, Patricia, Lopez-Fernández, Adria, Lopez-Perolio, Irene, Lorca, Victor, Loud, Jennifer T, Ma, Edmond S K, Mai, Phuong L, Manoukian, Siranoush, Mari, Veronique, Martin, Lynn, Matricardi, Laura, Mebirouk, Noura, Medici, Veronica, Meijers-Heijboer, Hanne E J, Meindl, Alfons, Mensenkamp, Arjen R, Miller, Clare, Gomes, Denise Molina, Montagna, Marco, Mooij, Thea M, Moserle, Lidia, Mouret-Fourme, Emmanuelle, Mulligan, Anna Marie, Nathanson, Katherine L, Navratilova, Marie, Nevanlinna, Heli, Niederacher, Dieter, Nielsen, Finn C Cilius, Nikitina-Zake, Liene, Offit, Kenneth, Olah, Edith, Olopade, Olufunmilayo I, Ong, Kai-Ren, Osorio, Ana, Ott, Claus-Eric, Palli, Domenico, Park, Sue K, Parsons, Michael T, Pedersen, Inge Sokilde, Peissel, Bernard, Peixoto, Ana, Pérez-Segura, Pedro, Peterlongo, Paolo, Petersen, Annabeth Høgh, Porteous, Mary E, Pujana, Miguel Angel, Radice, Paolo, Ramser, Juliane, Rantala, Johanna, Rashid, Muhammad U, Rhiem, Kerstin, Rizzolo, Piera, Robson, Mark E, Rookus, Matti A, Rossing, Caroline M, Ruddy, Kathryn J, Santos, Catarina, Saule, Claire, Scarpitta, Rosa, Schmutzler, Rita K, Schuster, Hélène, Senter, Leigha, Seynaeve, Caroline M, Shah, Payal D, Sharma, Priyanka, Shin, Vivian Y, Silvestri, Valentina, Simard, Jacques, Singer, Christian F, Skytte, Anne-Bine, Snape, Katie, Solano, Angela R, Soucy, Penny, Southey, Melissa C, Spurdle, Amanda B, Steele, Linda, Steinemann, Doris, Stoppa-Lyonnet, Dominique, Stradella, Agostina, Sunde, Lone, Sutter, Christian, Tan, Yen Y, Teixeira, Manuel R, Teo, Soo Hwang, Thomassen, Mads, Tibiletti, Maria Grazia, Tischkowitz, Marc, Tognazzo, Silvia, Toland, Amanda E, Tommasi, Stefania, Torres, Diana, Toss, Angela, Trainer, Alison H, Tung, Nadine, van Asperen, Christi J, van der Baan, Frederieke H, van der Kolk, Lizet E, van der Luijt, Rob B, van Hest, Liselotte P, Varesco, Liliana, Varon-Mateeva, Raymonda, Viel, Alessandra, Vierstraete, Jeroen, Villa, Roberta, von Wachenfeldt, Anna, Wagner, Philipp, Wang-Gohrke, Shan, Wappenschmidt, Barbara, Weitzel, Jeffrey N, Wieme, Greet, Yadav, Siddhartha, Yannoukakos, Drakoulis, Yoon, Sook-Yee, Zanzottera, Cristina, Zorn, Kristin K, D'Amico, Anthony V, Freedman, Matthew L, Pomerantz, Mark M, Chenevix-Trench, Georgia, Antoniou, Antonis C, Neuhausen, Susan L, Ottini, Laura, Nielsen, Henriette Roed, and Rebbeck, Timothy R

Abstract

Pathogenic sequence variants (PSV) in BRCA1 or BRCA2 (BRCA1/2) are associated with increased risk and severity of prostate cancer. We evaluated whether PSVs in BRCA1/2 were associated with risk of overall prostate cancer or high grade (Gleason 8+) prostate cancer using an international sample of 65 BRCA1 and 171 BRCA2 male PSV carriers with prostate cancer, and 3,388 BRCA1 and 2,880 BRCA2 male PSV carriers without prostate cancer. PSVs in the 3' region of BRCA2 (c.7914+) were significantly associated with elevated risk of prostate cancer compared with reference bin c.1001-c.7913 [HR = 1.78; 95% confidence interval (CI), 1.25-2.52; P = 0.001], as well as elevated risk of Gleason 8+ prostate cancer (HR = 3.11; 95% CI, 1.63-5.95; P = 0.001). c.756-c.1000 was also associated with elevated prostate cancer risk (HR = 2.83; 95% CI, 1.71-4.68; P = 0.00004) and elevated risk of Gleason 8+ prostate cancer (HR = 4.95; 95% CI, 2.12-11.54; P = 0.0002). No genotype-phenotype associations were detected for PSVs in BRCA1. These results demonstrate that specific BRCA2 PSVs may be associated with elevated risk of developing aggressive prostate cancer. SIGNIFICANCE: Aggressive prostate cancer risk in BRCA2 mutation carriers may vary according to the specific BRCA2 mutation inherited by the at-risk individual.

Published
2020

49. Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane

Author

O'Shaughnessy, Joyce, primary, Schwartzberg, Lee, additional, Piccart, Martine, additional, Rugo, Hope S., additional, Yardley, Denise A, additional, Cortes, Javier, additional, Untch, Michael, additional, Harbeck, Nadia, additional, Wright, Gail S., additional, Bondarenko, Igor, additional, Glaspy, John, additional, Nowecki, Zbigniew, additional, Kayali, Fadi, additional, Chan, Arlene, additional, Levy, Christelle, additional, Liu, Mei-Ching, additional, Kim, Sung-Bae, additional, Lemieux, Julie, additional, Manikhas, Alexey, additional, Tolaney, Sara, additional, Lim, Elaine, additional, Gombos, Andrea, additional, Stradella, Agostina, additional, Pegram, Mark, additional, Fasching, Peter, additional, Mangel, Laszlo, additional, Semiglazov, Vladimir, additional, Dieras, Veronique, additional, Gianni, Luca, additional, Danso, Michael A, additional, Vacirca, Jeff, additional, Kroll, Stew, additional, O'Connell, Joseph, additional, Tang, Kevin, additional, Wei, Thomas, additional, and Seidman, Andrew, additional

Published
2021
Full Text
View/download PDF

50. ERCC3, a new ovarian cancer susceptibility gene?

Author

Stradella, Agostina, primary, del Valle, Jesús, additional, Rofes, Paula, additional, Vargas-Parra, Gardenia, additional, Salinas, Mónica, additional, González, Sara, additional, Montes, Eva, additional, López-Doriga, Adriana, additional, Gómez, Carolina, additional, de Cid, Rafael, additional, Darder, Esther, additional, Teulé, Alex, additional, Solanes, Ares, additional, Munté, Elisabet, additional, Capellà, Gabriel, additional, Pineda, Marta, additional, Feliubadaló, Lidia, additional, Brunet, Joan, additional, and Lázaro, Conxi, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results